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Abstract
Background: Levodopa and dopamine agonists are the main treatments for Parkinson’s disease (PD) in recent
years. Increased drug dosages are linked to some severe side effects, one of which is impulse control disorders
(ICD). Many studies have reported the related risk factors of ICDs, such as dopamine agonist, male sex, younger age,
earlier age of onset and so on. This study aims to investigate the incidence of ICD in Chinese PD patients from
Shanghai area, explore the association of ICD with dopamine replacement therapy (DRT).
Methods: Two hundred seventeen PD patients were consecutively recruited from the Movement Disorder Clinic
of Ruijin Hospital from March to October 2013. Minnesota Impulsive Disorders Interview was used to assess the PD
patients. PD patients with possible ICD would undergo a further interview by a movement disorder specialist to
confirm the diagnosis. Clinical information was also collected.
Results: Nine PD patients (4.15 %) showed ICD behaviors as follows: hypersexuality (4, 1.84 %), pathological
gambling (3, 1.38 %), binge eating (1, 0.46 %), compulsive shopping (1, 0.46 %). Compared with the non-ICD PD
group, ICD PD group took more dopamine agonists (LED 119.4 ± 86.4 mg/d vs 60.5 ± 80.5 mg/d, P = 0.019), had
higher total levodopa equivalent dosage (TLED 912.81 ± 878.73 mg/d vs 503.78 ± 359.14 mg/d, P = 0.031), and had
higher H&Y stage (2.33 ± 0.87 vs 1.41 ± 0.52, p = 0.013). However, logistic regression analysis didn’t reveal the above
factors as independent risk factors of ICD behaviors in our study.
Conclusion: The incidence of ICDs behaviors in PD patients in our study is much lower than in western countries.
ICD-PD group took higher dopamine agonists and higher total levodopa equivalent dosage, even though logistic
regression analysis didn’t reveal them as independent risk factors.
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Background
Parkinson’s disease is associated with progressive degener-
ation of the nigrostriatal pathway that often impairs motor
skills (resting tremor, rigidity, bradykinesia and postural in-
stability). Dopaminergic replacement therapy (DRT), includ-
ing levodopa and dopamine agonists (DA agonists), relieves
the motor symptoms and improves quality of life. However,
a series of motor complications, such as dyskinesia and
wearing off, appear with the increased dosage of levodopa
and DA agonists [1, 2]. In recent years, PD patients have
been evidenced having increased risk of developing impulse
control disorders (ICDs) mainly because of DRT medica-
tion. ICDs have four major symptoms, pathological gam-
bling (PG), hypersexuality (HS), compulsive shopping (CS)
and binge-eating (BE) disorder. Excessive dopaminergic
medication usage, punding and aimless walkabout are also
considered as impusive/compulsive behaviors (ICB) [3, 4].
Lots of studies were conducted to explore the prevalence
and associated risk factors of ICDs. The most well-known
was DOMINION cross-sectional study (N = 3090 patients)
conducted by multi-centers in North America. In this
study, ICD prevalence was 13.6 % (PG 5.0 %, HS 3.5 %, CS
5.7 %, and BE 4.3 %). A wide spectrum of prevalence,
ranging from 3.53 % to 34.8 %, has been reported from
different studies [4–12], with higher prevalence in Western
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populations than in Asian generally. Different variables as-
sociated with ICDs have been revealed, including DA agonist
[4–6, 8, 10, 11], male sex (mainly in HS and PG) [4, 6–8, 12],
younger age [6–9], earlier age of onset [9], prior personal or
family history of alcohol addiction or gambling problems etc.
[6, 10, 13]. But, DA agonist was the most consistent risk
factor in those studies. In DOMINION study, DA agonist
treatment increased about 2- to 3.5-fold odds of having an
ICD, suggesting that there existed a close relationship
between DA agonists and ICDs [6]. Therefore we tried to
investigate the prevalence of ICDs among Chinese PD
patients from Shanghai area and explore the associated risk
factors, especially DA agonist medication. The underlying
reasons for different prevalence between Western population
and Asians were also discussed by reviewing literature.
Methods
Two hundred seventeen idiopathic PD patients, based
on UK Brain Bank clinical diagnostic criteria [14], were
recruited from the Movement Disorder Clinic at the
Department of Neurology of Ruijin Hospital from March
to October in 2013. Exclusion criteria included atypical
parkinsonism, secondary parkinsonism, and cognitive
abnormality that might have problem in understanding
and giving feedback of questionnaire. The study was ap-
proved by ethics committee of Ruijin Hospital.
The modified version of Minnesota Impulsive Disorders
Interview (Chinese version) was used to assess gambling,
compulsive shopping, hypersexuality, binge eating, and
punding. The questionnaire was performed by two gradu-
ates who had been well trained and the screened positive
patients were interviewed by a movement disorder spe-
cialist, and a final diagnosis was made according to the
diagnostic criteria listed in Voon et al’s paper [13].
Statistics
Statistical analysis was performed using SPSS 18.0, and
P < 0.05 was considered to be significant. Independent-
sample t-tests, non-parametric test and Fisher’s exact
test were used to compare age, disease duration, Hohn-
Yahr stage, gender, and dosage of anti-parkinsonian drugs
between PD patients with and without ICD behaviors.
Logistic regression was used to investigate the correlation
among the potential risk factors for ICD behaviors.
Results
Demographic characteristics
The clinical characteristics are listed in Table 1. There
were 120 male (55.3 %), and 97 female (44.7 %). The
mean age was 67.15 ± 0.61 years old (range: 40–85) and
mean disease duration was 5.78 ± 4.32 years (range:1–23).
All PD patients were taking anti-parkinsonian drugs.
Totally, 193(88.9 %) patients were taking levodopa with an
average daily dose 494.94 ± 348.03 mg/d (100-2825 mg/d),
101(46.5 %) patients were taking DA agonists, with a
dopamine agonists levodopa equivalent dosage (DA-LED)
135.15 ± 66.8 mg in average per day (ranging from 50 to
300 mg) and total levodopa equivalent dosage (TLED)
548.53 ± 382.12 mg/d (ranging from 50 to 3000 mg)
(Table 1).
Point prevalence and clinical features of ICD
Among 217 PD patients interviewed, 9 (4.15 %) patients
fulfilled criteria for ICDs and their behaviors and medi-
cations were listed in Table 2. Seven patients among
ICD group took both DA agonists and levodopa, two
patients took levodopa only. Overall, there was 1(0.46 %)
patient had CS, 1(0.46 %) patient had BE, 3(1.38 %)
patients had PG, 4(1.84 %) PD patients were diagnosed
with HS. All those patients showed ICD symptoms after
DRT therapy.
Clinical characteristics of PD with ICD group and
non-ICD PD group were listed in Table 3. There was no
significant difference of age, gender, and disease duration
between these two groups. But, for H-Y stage, ICD-PD
group had more severe disease condition than non-ICD
PD group (2.33 ± 0.87 vs1.41 ± 0.52, p = 0.013). In ICD
group, 7 (77.8 %) out of 9 patients took DA agonists, the
DA-LED was 119.4 ± 86.4 mg/d, 94 (45.2 %) of non-ICD
patients took DA agonists (DA-LED 60.5 ± 80.5 mg/d). The
dosage of DA agonists in ICD group was much higher than
non-ICD patients (P = 0.019). Patients in ICD group also
took more levodopa (791.67 ± 802.73 mg/d) than those
in non-ICD group (425.0 ± 327.26 mg/d), although this
difference didn’t reach the significant level (P = 0.066).
TLED was also calculated, ICD group took 912.81 ±
878.73 mg/d TLED, which was much higher than that
of non-ICD group (503.78 ± 359.13 mg/d) (P = 0.031).
Variables entered into the multiple logistic regression
Table 1 The demographic and clinical characteristics of PD
patients
Item mean ± SD Range
Number of cases 217
Male, n(%) 120 (55.3 %)
Age, year 67.15 ± 0.61 40-85
Disease duration, year 5.78 ± 4.32 1-23
H&Y stage 1.43 ± 0.55 1-4
Use of levodopa, n(%) 193 (88.9 %)
Use of DA agonists, n(%) 101 (46.5 %)
Levodopa, (mg/d) 494.94 ± 348.03 100-2825
DA agonist LED, (mg/d) 135.15 ± 66.8 50-300
TLED, (mg/d) 548.53 ± 382.12 50-3000
Note:DA agonist-LED (DA-LED, mg/d) = piribedil (mg/d) × 1 + pramipexole (mg/
d) × 100. Total LED (TLED, mg/d) = regular levodopa dose (mg/d) × 1 + levodopa
CR dose (mg/d) × 0.75 + DA-LED, and plus [regular levodopa dose (mg/d) + CR
levodopa dose(mg/d) × 0.75] × 0.33 if taking COMT-I [24]
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analysis were: gender, age, disease duration, use of ago-
nists, dosage of levodopa, DA-LED, TLED and H-Y
stage. Our results didn’t reveal any independent risk
factors for ICD behaviors (data was not shown).
Comparison with Previous studies
A wide range of ICDs prevalence and variable risk factors
of ICDs from different studies have been reported
(Table 4). Generally, prevalence of ICDs in Asian coun-
tries (3.53 %-5.9 %) [4, 10, 11] was lower than Western
countries (8.1 %-34.8 %) [5–8], except studies from Japan
with 12.9 % of ICD [9] and Malaysia with 15.4 % of
screen positive ICD [12]. Lower DA agonist medica-
tion, ethnic differences, social factors, and culture dif-
ferences have been considered as potential factors
influencing different prevalence [4, 10, 11]. But we
found that screening instruments might be another in-
fluencing factor. As listed in Table 4, a variety of screen
questionaires, such as Questionnaire for Impulsive
Compulsive Disorders in Parkinson’s Disease (QUIP),
Minnesota Impulsive Disorders Interview (MIDI) and a
list of screen/diagnostic tests for PG, HS and CS, were
used in these studies. Studies using QUIP as screen instru-
ment reported high rate of screen positive ICD patients,
28 % in Japan [9], 15.4 % in Malaysia [12], 34.8 % in
Finland [7] and 18.4 % in Brazil [5]. In this Japan study,
the actual prevalence of ICDs assessed by various diagnos-
tic criteria for each ICD turned out to be 12.9 %. Thus,
QUIP might be an optimal instrument for screening ICDs
because of its high sensitivity, but further diagnostic cri-
teria is needed for confirmative diagnosis.
Discussion
Previous reports estimated the frequency of ICDs in PD
patients ranged from 3.53 % to 34.8 % [4–12]. Two reports
from Xuanwu Hospital Beijing China and ChangGung
Memorial Hospital Taiwan reported the rates of ICDs in
PD patients are 3.53 % and 4.48 % respectively [4, 10].
ICD frequency in our study was estimated at 4.15 %.
These studies carried out among Chinese PD patients got
similar results.
By comparison with Western countries reports, results
from Asian studies showed a relatively low incidence of
ICD except studies from Japan with 12.9 % of ICD [9]
and Malaysia with 15.4 % of ICD [12]. Point prevalence
of ICDs from China, Taiwan, South Korea and present
study showed a range from 3.53 % to 5.9 % [4, 10, 11],
while data from North America, Brazil, Italy, Finland
showed higher prevalence 8.1 % ~ 34.8 % [5–8]. Note
that studies from Malaysia, Brazil and Finland reported
high frequency of ICDs only by QUIP screen without
further confirmative diagnosis. Besides that, a variety of
reasons have been considered for different prevalence.
Lower dosage of DA agonists because of medication
practice, cost burden, limited availability and health in-
surance [10] has been suggested as a potential factor af-
fecting different prevalence. Other factors, such as
ethnic differences, social factors, study design, culture
difference, were also considered [4–12]. Genetic factors
Table 2 ICD behaviors in patients with Parkinson’s disease
case gender age PD duration H&Y stage concurrent medication DA-LED TLED ICD behaviors
1 M 75 6 3 L-DA+ pra 200 1100 PG
2 M 67 4 2 L-DA 0 300 PG
3 M 69 3 2 L-DA+ pra 150 450 HS
4 F 62 5 1 L-DA+ pra 150 825 CS
5 M 49 8 3 L-DA+ pra 225 3000 HS
6 M 50 5 3 L-DA+ pra 200 500 HS
7 F 73 10 3 L-DA 0 600 BE
8 F 51 4 2 L-DA + pir 100 300 PG
9 M 68 10 3 L-DA + pir + ent 50 1014.25 HS
Note: pra = pramipexole; pir = piribedil; ent = entacapone
PG = pathological gambling; HS = hypersexuality; CS = compulsive buying; BE = binge-eating disorder
Table 3 Comparison between patients with and without ICD
behaviors (mean ± SD, n, %, p)
Non-ICD ICD P value
Number of case 208 9
Age, year 67.25 ± 8.82 63.67 ± 10.55 0. 469
Male, n(%) 114 (54.8 %) 6 (66.7 %) 0.521
Disease duration, year 5.76 ± 4.38 6.44 ± 3.17 0.33
Dose of levodopa, (mg/d) 425.0 ± 327.26 791.67 ± 802.73 0.066
DA - LED, (mg/d) 60.5 ± 80.5 119.4 ± 86.4 0.019*
TLED, (mg/d) 503.78 ± 359.13 912.81 ± 878.73 0.031*
H&Y stage 1.41 ± 0.52 2.33 ± 0.87 0.013*
Use of agonists, n(%) 94(45.2 %) 7 (77.8 %) 0.055
*p < 0.05 ICD vs Non-ICD group
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have also been revealed. Polymorphism of dopamine re-
ceptor D3 and D2, serotonin 2A receptor gene (HTR2A)
have been linked with ICDs [15–17].
However, here we want to emphasize screen instru-
ments as a potential reason for different prevalence. Study
from Japan reported 28 % ICDs by QUIP screen and
12.9 % actual prevalence by other diagnostic criteria [9],
indicating QUIP is a screening test with high sensitivity
but relatively low specificity. QUIP is a comprehensive
screening test and can evaluate a wide range of impulsive
compulsive behaviors [18]. In our study, we used MIDI
for screen test. MIDI and QUIP are different in design.
MIDI has 5 modules with 1 module for each ICD. Each
module has one Yes/No question for preliminary screen,
and the Yes/No answer largely depends on the patients or
informants’ rough judgement. In QUIP test with session 1
as an example, for each ICD there are 5 specific questions
from different perspectives collecting patients’ feelings
and experiences, and patients or informants can make a
fine judgement based on those 5 questions. Thus, MIDI is
a quick and convenient battery for clinical work, while
QUIP is more comprehensive and sensitive for both
research and clinical work. But, to get a final diagnosis,
other diagnostic criteria were needed. In our study, diag-
nostic criteria listed by Voon et.al [13] were adopted.
With regard to potential risk factors for ICDs identified
in previous analyses, such as younger age, male sex, earlier
age of disease onset, were not revealed as independent risk
factors for development of ICDs in our study. Many
researchers have confirmed that DA agonist was a main
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sexcurrent smokingbeing
unmarriedliving in the United
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gambling
DA-LED: 200 ~ 450 vs 150
~ 400(listed as interquartile
in patients taking




Finland 575 SOGSQUIP QUIP results:ICD 34.8 % PG






Italy 805 QUIP for screenOther
criteria for confirmation
ICD 8.1 % PG 3.2 %, HS





Japan 118 QUIP for screenOther
criteria for confirmation
QUIP results vs Actual
prevalenceICD 28 % vs
12.9 % PG 14 % vs 6.5 %
HS 14 % vs 3.2 % CS 10.8 %
vs 3.2 % BE 10.8 % vs 3.2 %
younger agelonger disease
durationTLEDD,
LevodopaEarlier age of onset
ICB vs non-ICBLevodopa:
676 vs 520DA-LED: 139 vs
71.6
9





ICD 3.53 % PG 0.32 %, HS
1.92 % CS 0.32 %, BE 0.32 %






1167 MIDI ICD 5.9 % PG 1.3 %, HS
2.8 % CS 2.5 %, BE 3.4 %
Dopamine agonistLevodopa Levodopa: 656 vs
544DA-LED: 145 vs 99
11
Malaysian 200 QUIP QUIP results based on
patient reportICD 15.4 %
PG 2.6 %, HS 8.2 % CS









(2007) for each ICD
ICD 4.15 % PG 1.38 %, HS
1.84 % CS 0.46 %, BE 0.46 %
None Levodopa: 791.67 vs
425.0DA-LED: 119.4 vs 60.5
–
SOGS: modified South Oaks Gambling Screen. QUIP: Questionnaire for Impulsive Compulsive Disorders in Parkinson’s Disease
MIDI: Minnesota Impulsive Disorders Interview. ICB: impulsive compulsive behavior
DA-LED: Dopamine agonist levodopa equivalent dosage. TLED: Total levodopa equivalent dosage
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risk factor for ICDs [4–6, 8–11, 19]. However, logistic
regression analysis didn’t reveal it as an independent risk
factor for ICD in our study. Failing to identify DA agonist
as a risk factor might due to several reasons. First, the
main reason might be lower average daily dosage of DA
agonists (ICD vs non-ICD: 119.4 ± 86.4 vs 60.5 ± 80.5 mg/
d) taken by our patients compared with other studies
listed in Table 4. Study from Malaysia didn’t find correl-
ation between DA agonist and ICD either. There were
less than 50 % PD patients taking DA agonist and the
average daily dosage of DA agonist was 73.7 ± 84.3 mg in
that study [12]. Therefore, high dosage of DA agonist
places patients in a higher risk condition. Lower dosage
might cover the potential relationship between drugs and
development of ICD in this study. Second, it might be due
to sample and area limitation in our study. PD patients
enrolled in our study were mainly from Shanghai. Larger
sample and a multi-center based study would be a better
option to explore risk factors in Chinese population.
Although failing to identify DA agonist as a risk factor,
we found a higher percentage of ICDs patients took DA
agonists and a higher average daily DA agonist dosage
than that of non-ICD patients, which also indicates DA
agonist might be a potential risk factor for those PD-
ICD patients. One patient with HS behavior in our study
got recovered by discontinuation of pramipexole. Previ-
ous study showed successful management of the PD
patient with ICD by reduction or discontinuation of DA
agonist therapy [19–23]. Seven of 18 PD patients with
an ICD had resolution of the behavior by discontinu-
ation or dosage reduction of a DA agonist [22]. A
43 months follow–up study showed that nearly 73 % of
PD patients with ICD behaviors were completely recov-
ered after reducing dosage of DA drugs [23]. At present,
there were very limited data to support an effective
medicine for treatment of ICD behaviors in PD. Reduc-
tion or discontinuation of DA agonist is generally ac-
cepted as the first line management strategy of ICDs
[23], especially for those PD patients had ICD behaviors
after DRT therapy.
Conclusions
In conclusion, the incidence of ICDs behaviors in PD pa-
tients in our study is much lower than in western countries.
Routine screening of ICDs in PD patients is necessary to
discover PD-ICD patients and give early intervention.
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